Intra-articular and intravenous infliximab in the treatment of resistant seronegative oligoarthritis of the knee

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-015810-23

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary question is what is the optimal treatment for patients with resistant oligoarthritis. The primary outcome is reduction in synovitis seen on US scan at 8 weeks following administration of IA steroid (standard care), IA infliximab or IV infliximab.


Critère d'inclusion

  • Seronegative oligoarthritis (inflammatory arthritis of 4 active joints or less)

Liens